Alpha-GPC — Research Profile

Alpha-GPC delivers more choline per gram (40% vs 18%) and has stronger evidence for athletic performance. CDP-Choline (citicoline) provides additional uridine, which supports dopamine and neuronal membrane synthesis. For pure choline delivery and power output, choose Alpha-GPC. For broader nootropic and neuroprotective effects, CDP-Choline may be preferred.

A small study ^[2][3] showed a significant GH spike when Alpha-GPC was taken before exercise. However, this acute increase is transient and unlikely to produce meaningful anabolic effects comparable to exogenous GH. The athletic benefits of Alpha-GPC are more reliably attributed to enhanced neuromuscular function via increased acetylcholine.

Yes. Headaches are the most common side effect and are typically caused by excess acetylcholine. This is especially likely when stacking Alpha-GPC with other cholinergics. Reducing the dose to 150-300mg usually resolves the issue. Starting at a lower dose and gradually increasing is recommended.

Alpha-GPC is itself a single defined compound (L-alpha-glycerylphosphorylcholine, or choline alfoscerate), so "form" here means capsule versus powder rather than distinct chemical variants. Trials have used oral capsules, tablets, and solution, and none has compared delivery formats head-to-head. It should not be confused with other choline donors such as CDP-choline (citicoline) or choline bitartrate, which are different molecules with their own separate evidence.

The best-supported benefit is easing cognitive symptoms in mild-to-moderate Alzheimer's dementia: 400 mg three times daily for 180 days improved ADAS-Cog and other scales versus placebo (id 1). A single 1,000 mg dose acutely raised growth hormone and markers of fat oxidation in healthy young adults (id 3), and 7 days of 250-500 mg produced modest countermovement-jump power gains in recreationally trained men, though strength measures were unchanged (Marcus2017). Evidence that it sharpens memory or focus in healthy, non-elderly people is limited and inconsistent.

Dosing depends on the goal and no single standard is established. The dementia trial used 1,200 mg/day as 400 mg three times daily (id 1); acute growth-hormone and metabolic effects were seen at a single 1,000 mg dose (id 3); and physical-performance studies used 250-500 mg/day (Marcus2017). Most consumer nootropic products fall in the 300-600 mg range, all comfortably below the choline upper limit of 3,500 mg/day for adults (ODS).

Time of day has not been directly compared. In the Alzheimer's trial it was given three times daily with meals (id 1). For exercise-related effects, a dose raises choline and growth hormone within about 60 minutes (id 3), so performance studies administered it shortly before training, although daily dosing over several days also worked (Marcus2017). No evidence favors morning versus evening for general cognitive use.

In the 180-day dementia trial, choline alphoscerate was described as tolerable, but the study did not publish a placebo-controlled breakdown of adverse events (id 1), so no trial-quantified side-effect rate exists; effects reported in practice include headache, heartburn, nausea, dizziness, and insomnia. At high choline intakes generally, a fishy body odor, vomiting, excessive sweating and salivation, hypotension, and liver toxicity can occur (ODS). The more consequential concern is the observational link between longer choline alphoscerate use and higher stroke risk in older adults (adjusted HR 1.46 for total stroke), rather than these acute effects (Lee-Stroke).

No formal drug-interaction trials have been published for Alpha-GPC. Because it is a cholinergic compound that increases acetylcholine-precursor availability, it could in theory add to cholinergic drugs such as cholinesterase inhibitors used in dementia, or oppose anticholinergic medications, so anyone on those drugs should seek medical advice. Given the dose-dependent association with higher stroke risk in older users (Lee-Stroke), caution is also reasonable for older adults on cardiovascular or antithrombotic therapy, though no direct interaction has been demonstrated.

The clearest candidates are older adults with mild-to-moderate cognitive impairment, where 1,200 mg/day improved dementia symptoms under medical supervision (id 1); power and strength athletes sometimes use 250-500 mg for modest, inconsistent performance effects (Marcus2017). It is not proven to sharpen cognition in healthy younger adults. Adults with elevated stroke or cardiovascular risk should be cautious given the dose-dependent stroke association seen in older users, and there are no safety data supporting use in pregnancy, breastfeeding, or children (Lee-Stroke).

Onset depends entirely on the goal. Acute physiological effects are fast: a single 1,000 mg dose raised plasma choline and growth hormone within 60 minutes in healthy young adults (id 3). Small jump-power gains appeared after about 7 days of daily 250-500 mg in recreationally trained men (Marcus2017), while the cognitive benefit in mild-to-moderate Alzheimer's disease was measured over 90-180 days of 400 mg three times daily (id 1). No reliable onset data exist for cognitive enhancement in healthy people.

The longest well-controlled trial gave 1,200 mg/day (400 mg three times daily) for 180 days to mild-to-moderate Alzheimer's patients and described choline alphoscerate as tolerable, though its abstract did not report a placebo-controlled comparison of adverse-event rates (id 1). Separately, a retrospective South Korean cohort of about 12 million adults aged 50+ found choline alphoscerate users had a higher 10-year stroke risk (adjusted HR 1.46, 95% CI 1.43-1.48 for total stroke), with risk rising for treatment longer than 12 months (Lee-Stroke). That association is observational rather than proven causal, but it means genuine long-term safety is not established and older adults with vascular risk should be cautious.

There is no upper limit set specifically for Alpha-GPC, but because it delivers choline, the NIH tolerable upper intake level for total choline applies: 3,500 mg/day for adults 19+ and 3,000 mg/day for ages 14-18 (ODS). Choline intakes above that threshold can cause a fishy body odor, vomiting, excessive sweating and salivation, and low blood pressure, and choline raises TMAO in a dose-dependent way (ODS). Typical Alpha-GPC doses of 300-1,200 mg sit well below the choline upper limit.

No controlled trial has tested Alpha-GPC combined with another supplement for added benefit, so popular stacks (for example with caffeine or other nootropics) are unproven. The one concrete caution is stacking multiple choline sources at once, such as Alpha-GPC plus citicoline, lecithin, or a high-egg diet, since total choline drives TMAO production and should stay under the 3,500 mg/day choline upper limit for adults (ODS).

Alpha-GPC is strongly moisture-absorbing and is often sold as a roughly 50% powder bound to a carrier, so check whether the labeled milligrams refer to the finished blend or the actual Alpha-GPC content, and favor products with third-party identity and purity testing. The material studied in clinical trials is pharmaceutical-grade L-alpha-glycerylphosphorylcholine, also called choline alfoscerate (id 1), so a clear statement of the compound and its actual dose matters more than proprietary-blend marketing.